The molecular PD findings reported in this analysis are consistent with the differential clinical responses observed between guselkumab and ADA treatment in the VOYAGE 1 study and correlate with the depth of therapeutic responses seen with guselkumab versus ADA treatment in patients with moderate-to-severe psoriasis. Here, ADA is linked to psoriasis.